Glioblastoma (GBM) is the most lethal form of brain tumor and remains a large, unmet medical need. This review focuses on recent advances in the neurosciences that converge with the broader field of immuno-oncology. Recent findings in neuroanatomy provide a basis for new approaches of cellular therapies for tumors that involve the CNS. The ultimate success of immunotherapy in the CNS will requi...

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and still remains incurable. Although immunotherapeutic vaccination against GBM has demonstrated immune-stimulating activity with some promising survival benefits, tumor relapse is common, highlighting the need for additional and/or combinatorial approaches. Recently, antibodies targeting immune checkpoints were demo...

von Hippel-Lindau (VHL) disease is an autosomal dominant inherited tumor syndrome associated with mutations of the VHL tumor suppressor gene located on chromosome 3p25. The loss of functional VHL protein contributes to tumorigenesis. This condition is characterized by development of benign and malignant tumors in the central nervous system (CNS) and the internal organs, including kidney, adrena...

Extracellular vesicles (EVs) are particles released by multiple cells, encapsulated lipid bilayers and containing a variety of biological materials, including proteins, nucleic acids, lipids metabolites. With the advancement separation characterization methods, EV subtypes their complex diverse functions have been recognized. In central nervous system (CNS), EVs involved in various physiologica...

developed the neurological events while on treatment. CNS in volvement in Choriocarcinoma can be due to hemorrhagic metastas, tumor embolization and chemotherapy (especially platinum compounds). CNS thrombotic events are extremely rare. The association between cancer and thrombosis was identified in 1865 and the combination is called as Trousseau syndrome.[2] The mechanisms elucidated include c...

Abstract BACKGROUND Breast cancer is one of the most common cancers associated with brain metastases (BM). Up to 50% patients metastatic triple-negative breast (TNBC) develop BM which portends a poor prognosis, median survival 4.4-7.3 months. There lack effective systemic therapy. Irinotecan topoisomerase-1 inhibitor response rate 5-23% in advanced cancer. Nal-IRI an intravenous liposomal formu...